State Action
CCAGW Urges Michigan Legislators to Oppose Senate Bill 1179
Senate Bill 1179 will change how the federal 340B Drug Pricing Program operates in Michigan.
CCAGW Urges Michigan Legislators to Oppose Senate Bill 659
S.B. 659 will fail to achieve its objective of protecting consumer privacy.
CCAGW Urges Michigan Legislators to Oppose House Bill 5350
House Bill 5350 will change how the federal 340B Drug Pricing Program operates in Michigan.
CCAGW Urges North Carolina Senators to Oppose HB 246
HB 246 would impose onerous regulations on pharmacy benefit managers.
CCAGW Urges California Assembly to Oppose SB 966
SB 966 would insert the government further into the healthcare system and result in higher costs and fewer choices for patients in California.
CCAGW Urges St. Petersburg City Council to Reconsider Stadium Funding Proposal
St. Petersburg should reject the publicly-funded Rays stadium proposal and consider alternative development plans that don't burden taxpayers.
CCAGW Urges Ohio Representatives to Oppose House Bill 505
HB 505 would create unnecessary regulatory barriers that will undermine the effectiveness of pharmacy networks in Ohio.
CCAGW Urges Minnesota Legislators to Remove 340B Mandate from S.F. 4942
SF 4942's manufacturer mandate would change how the federal 340B drug pricing program operates in Minnesota.
CCAGW Urges Vermont Senators to Oppose H. 121
H. 121 will fail to achieve its objective of protecting consumer privacy
CCAGW Urges Kansas Senate Ways and Means Committee to Accept the 340B Amendment
The Kansas House Appropriations Committee’s amendment to Substitute for SB514 eliminates proposed changes to the federal 340B drug pricing program.
CCAGW Urges Missouri Senators to Oppose Senate Bills 751, 843, 844, and 1105
S.B. 751, S.B. 843, S.B. 844, and S.B. 1105 which would each create unnecessary regulatory barriers that will undermine the effectiveness of pharmaceutical benefit managers (PBMs) in Missouri.
CCAGW Urges Missouri Representatives to Oppose House Bills 1627, 1628 and 2267
H.B. 1627, H.B. 1628, and H.B. 2267 would each create unnecessary regulatory barriers that will undermine the effectiveness of pharmaceutical benefit managers (PBMs) in Missouri.
